GSK-Partnered Alector Hit By Renewed Dementia Skepticism
Doubts About Biomarker
Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker
You may also be interested in...
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.
Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.